Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Matthew Ho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Lymphoma, Non-Hodgkin, Multiple Myeloma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
The success of chimeric antigen receptor T‐cell (CAR‐T) therapy in hematologic malignancies has realized a longstanding effort toward harnessing the immune system to fight cancer in a truly personalized fashion. Second generation chimeric antigen receptors (CAR) incorporating co‐stimulatory molecules like 4‐1BB or CD28 were able to overcome some of the hindrances with initial CAR constructs resulting in efficacious products. Many second‐generation CAR‐T products have been approved in the treatment of relapsed/refractory hematologic malignancies including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia. However, challenges remain in optimizing the manufacturing, timely access, limiting the toxicity from CAR‐T infusions and improving sustainability of responses derived with CAR‐T therapy. Here, we summarize the clinical trial data leading to approval CAR‐T therapies in MM and NHL, discuss the limitations with current CAR‐T therapy strategies and review emerging strategies for overcoming these limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Matthew Ho, Saurabh Zanwar, Jonas Paludo
Zitieren
APA
Ho, M., Zanwar, S., & Paludo, J. (2024). Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities. European Journal of Haematology. https://doi.org/10.1111/ejh.14074
Vancouver
Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities. European Journal of Haematology. 2024. doi:10.1111/ejh.14074
BibTeX
@article{Ho2024,
author = {Ho, Matthew and Zanwar, Saurabh and Paludo, Jonas},
title = {Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14074}
}
EUVIMED